Title:Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Volume: 1
Issue: 1
Author(s): Hua Yao, Chenwei Yang, Ling Shen, Xinhua Gu, Changyan Chen, Xianglin Shi and Zhuo Zhang
Affiliation:
Keywords:
Angiogenesis, anti-angiogenesis strategy, dietary compounds, head and neck squamous cell carcinoma, targeted
therapy, vascular endothelial growth factor
Abstract: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide. Following
the conventional treatment, most patients with advanced HNSCC often face a considerable risk of locoregional disease recurrence,
due to the occurrence of the resistance to therapy or of metastasis. Despite continued advances in the therapeutic
options, the traditional therapies conducted in HNSCC to date have largely lacked efficacy or associated with significant
toxicity. Angiogenesis plays an important role in HNSCC initiation and progression. Recently, targeted angiogenesis therapy
draws a broad attention, because it can specifically enhance the efficacy of chemotherapy without an increased toxicity
profile. Numerous ongoing preclinical studies and clinical trials exploring anti-angiogenetic inhibitors are being tested
in HNSCC. Integration targeted angiogenesis therapy with the traditional modalities of surgery, radiotherapy, and cytotoxic
chemotherapy for HNSCC might be a direction in the future. This review discussed current knowledge of the targeted
angiogenesis therapies, recent development of anti-angiogenesis agents, and summaries of the clinical evaluation on
use of these therapies for HNSCC.
